Previous 10 | Next 10 |
ROCHESTER, Mich., Feb. 23, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, will hold a conference call on Wednesday, March 8, 2023 at...
ROCHESTER, Mich., Feb. 09, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced its senior vice president of access and adherence,...
OPRX CEO Will Febbo provides business update and key industry trends OPRX conference presentation to begin at 8:15 AM PT on January 12, 2023 ROCHESTER, Mich., Jan. 04, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading ...
ROCHESTER, Mich., Nov. 28, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced that management will participate in the following...
OptimizeRx Corporation (OPRX) Q3 2022 Earnings Conference Call November 8, 2022 16:30 ET Company Participants Will Febbo - Chief Executive Officer Ed Stelmakh - Chief Financial and Operating Officer Steve Silvestro - Chief Commercial Officer Marion Odence-For...
OptimizeRx press release ( NASDAQ: OPRX ): Q3 Non-GAAP EPS of $0.07 beats by $0.03 . Revenue of $15.1M (-6.3% Y/Y) beats by $0.08M . Gross profit in the third quarter of 2022 increased 4% year-over-year to $9.4 million. Cash, cash equivalents and short-term...
Q3 Revenue of $15.1 million, down 6% year-over-year and up 8% quarter-over-quarter Gross profit increased 4% year-over-year to $9.4 million as gross margins increased from 56% to 62% Generated $7.9 million in cash flow from operations during the first nine months of 2022 Rep...
OptimizeRx ( NASDAQ: OPRX ) is scheduled to announce Q3 earnings results on Tuesday, November 8th, after market close. The consensus EPS Estimate is $0.04 (-55.6% Y/Y) and the consensus Revenue Estimate is $15.02M (-6.8% Y/Y). Over the last 2 years, OPRX has beaten E...
Summary Shares of digital healthcare marketing firm OptimizeRx Corporation have cratered 86% in just 11 months as an initial FY22 revenue growth projection has been revised from 35% to 6%. A slowdown in FDA approvals has been blamed, but the stock was wildly overvalued, trading at...
ROCHESTER, Mich., Oct. 20, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced the third annual Innovate4Outcomes ® event...
News, Short Squeeze, Breakout and More Instantly...
OptimizeRx Corporation Company Name:
OPRX Stock Symbol:
NASDAQ Market:
OptimizeRx Corporation Website:
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a confere...
WALTHAM, Mass., July 23, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced its conti...
WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the resul...